Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic, multicenter, placebo-controlled GLORIA trial

Hartman, LindaEl Alili, M.Cutolo, MaurizioOpris, DanielaDa Silva, J. A. P.Szekanecz, ZoltánButtgereit, FrankMasaryk, PavolBos, ReinhardKok, Marc R.Paolino, SabrinaCoupé, V. M. H.Lems, Willem F.Boers, Maarten2022-11-102022-11-102022Seminars In Arthritis And Rheumatism. -57 (2022), p. 1-8. -Semin. Arthritis Rheum. - 0049-01720049-0172https://hdl.handle.net/2437/339351Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic, multicenter, placebo-controlled GLORIA trialfolyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM105027OrvostudományokKlinikai orvostudományokhttps://linkinghub.elsevier.com/retrieve/pii/S0049017222001603szerzőhttp://dx.doi.org/10.1016/j.semarthrit.2022.1521092022-11-1000104294540000585140434684